## **Electronic Supplementary Information**

## ES-MIONs Based Dual-modality PET/MRI Probes for Acidic Tumor Microenvironment Imaging


Xiuyan Wei<sup>1 §</sup>, Haitao Zhao<sup>2 §</sup>, Gang Huang<sup>3</sup>, Jianhua Liu<sup>1</sup> \*, Weina He<sup>1</sup> \*, Qingqing Huang<sup>3</sup> \*

- 1 Medical Chemistry and Bioinformatics Center, College of Basic Medical Sciences, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
- 2 Department of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China.
- 3 Shanghai Key Laboratory of Molecular Imaging, Shanghai University of Medicine and Health Sciences, Shanghai 201318, China

\* E-mail: jhliu7912@sjtu.edu.cn (J. Liu); hewn0319@sjtu.edu.cn (W. He); qingqinghuang80@gmail.com (Q. Huang)

<sup>§</sup>These authors contributed equally to this work.

**Figure S1.** Synthesis route of Fe<sub>3</sub>O<sub>4</sub>-PEG-DOTA/pHLIP NPs.



**Figure S2.** Magnetization curves of citrate-stabilized Fe<sub>3</sub>O<sub>4</sub> NPs measured at 298K and 309K.





Figure S3. FTIR spectra of (a) NH<sub>2</sub>-PEG-pHLIP and (b) NH<sub>2</sub>-PEG-DOTA.



**Figure S4.**  $^{1}$ H NMR spectra of (a) DOTA-NHS, (b) Var3 pHLIP, (c) NH<sub>2</sub>-PEG-Fmoc, (d) NH<sub>2</sub>-PEG-Mal, (e) NH<sub>2</sub>-PEG-DOTA and (f) NH<sub>2</sub>-PEG-pHLIP.







Figure S5. Size distribution of citrate-stabilized Fe<sub>3</sub>O<sub>4</sub> NPs with Gaussian fitting.




 $\label{eq:Figure S6.} \textbf{Fe_3O_4} \quad \text{TEM} \quad \text{images} \quad \text{and} \quad \text{(b)} \quad \text{SAED} \quad \text{patterns} \quad \text{of} \quad \text{citrate-stabilized} \quad \text{Fe_3O_4} \quad \text{NPs}, \\ \text{Fe_3O_4-PEG-DOTA NPs} \quad \text{and} \quad \text{Fe_3O_4-PEG-DOTA/pHLIP NPs}.$ 




**Figure S7.** (a) Phantom images acquired from  $T_1$ -weighted and  $T_2$ -weighted MRI scans for  $Fe_3O_4$ -PEG-DOTA NPs at different Fe concentrations at the room temperature 32-34  $^{\circ}$ C and pH 6.8. (b) Plot of the relaxation rates of  $Fe_3O_4$ -PEG-DOTA NPs as a function of Fe concentration at the room temperature 32-34  $^{\circ}$ C and pH 6.8.



**Figure S8.** T<sub>1</sub>-weighted MR imaging of Fe<sub>3</sub>O<sub>4</sub>-PEG-DOTA and Fe<sub>3</sub>O<sub>4</sub>-PEG-DOTA/pHLIP NPs at the Fe concentrations of 0.3125, 0.625, 1.25, 2.50, 5.00, 10.00 mM, respectively.



**Figure S9.** Cytotoxicity of 4T1 cells after treated with the (a)  $Fe_3O_4$ -PEG-DOTA NPs and (b)  $Fe_3O_4$ -PEG-DOTA/pHLIP NPs at different Fe concentrations for 24 h. 4T1 cells treated with PBS were used as control.



**Figure S10.** Whole-body PET/CT imaging on mice at 15 min, 40 min, 75 min, 105 min after the intravenous injection of Fe<sub>3</sub>O<sub>4</sub>-PEG-[<sup>68</sup>Ga]DOTA/pHLIP NPs or Fe<sub>3</sub>O<sub>4</sub>-PEG-[<sup>68</sup>Ga]DOTA NPs.

**Table S1.** Mean signal strength of in vitro tumor cellular uptake of Fe<sub>3</sub>O<sub>4</sub>-PEG-[<sup>68</sup>Ga]DOTA/pHLIP NPs and Fe<sub>3</sub>O<sub>4</sub>-PEG-[<sup>68</sup>Ga]DOTA NPs of 4T1 cells in pH 6.0, 6.4, 6.9, 7.4 respectively.

pН	Fe <sub>3</sub> O <sub>4</sub> -PEG-DOTA/pHLIP NPs (cpm)	Fe <sub>3</sub> O <sub>4</sub> -PEG-DOTA NPs (cpm)
6.0	9130	3172
6.4	6507	3390
6.9	6603	3133
7.4	4493	3196